Polyethylene glycol conjugated interleukin-2 : clinical and immunologic effects in patients with advanced renal cell carcinoma

Recombinant interleukin-2 (rIL-2) modified with monomethoxypolyethylene glycol (PEG IL-2) was utilized in patients with metastatic renal cell carcinoma in two separate multi-institutional trials. PEG IL-2 was administered as an I.V. bolus days 1, 8, 15, and 22 with cycles repeated every six weeks. T...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 1993-06, Vol.11 (2-3), p.211-217
Hauptverfasser:	BUKOWSKI, R. M, YOUNG, J, GOODMAN, G, MEYERS, F, ISSELL, B. F, SERGI, J. S, MCLAIN, D, FYFE, G, FINKE, J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Biological and medical sciences Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - immunology Dose-Response Relationship, Drug Female Humans Immunotherapy Interleukin-2 - adverse effects Interleukin-2 - analogs & derivatives Interleukin-2 - therapeutic use Kidney Neoplasms - drug therapy Kidney Neoplasms - immunology Male Medical sciences Middle Aged Pharmacology. Drug treatments Polyethylene Glycols
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!